ValiRx Share News (VAL)

ValiRx interim loss widens as costs increase; hails Inaphaea progress

(Alliance News) - ValiRx PLC on Thursday reported an increased half-year loss amid higher costs, as it continued to focus on building its science-focused portfolio.

ValiRx shares jump as H1 losses shrink

(Sharecast News) - Shares in ValiRx jumped nearly on Thursday after the biotech posted results for its first half, in which losses per share shrunk by a third.

ValiRx subsidiary Inaphaea signs deal with Agility Life Sciences

(Sharecast News) - Life science company ValiRx announced on Monday that its wholly-owned subsidiary Inaphaea BioLabs has entered a collaborative services agreement with Agility Life Sciences.

ValiRx signs collaborative services agreement with Agility

(Alliance News) - ValiRx PLC on Monday said its wholly-owned subsidiary, Inaphaea BioLabs Ltd, has entered into a collaborative services agreement with Agility Life Sciences Ltd.

IN BRIEF: ValiRx subsidiary secures contract with UK biotech firm

ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphea BioLabs Ltd will partner with an unnamed UK-based biotechnology company on a phenotypic assay to investigate anti-cancer properties using patient-derived cells from Inaphea's biobank. Adds Inaphea has started internal studies on ValiRx assets s VAL301 and Cytolytix CLX001. "This defined work programme involves a multi-stage project and is expected to complete at the end of September 2023," ValiRx says.

TRADING UPDATES: All Things Considered raises funds to buy Sandbag

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News:

UK shareholder meetings calendar - next 7 days

IN BRIEF: ValiRx subsidiary to supply cell-based assays to OncoBone

ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women's health - Says subsidiary Inaphaea Biolabs Ltd enters agreement with OncoBone Ltd. Says OncoBone clients will be able to access Inaphaea services. Notes Inaphaea is now confirmed as a cell-based assay supplier to OncoBone. Adds Inaphaea's services are now listed on scientist.com, a database website used by biotechnology and pharmaceutical companies.

ValiRx terminates collaboration with Hokkaido University

(Sharecast News) - Life science company ValiRx has officially concluded its evaluation agreement with Hokkaido University, it announced on Friday.

AIM WINNERS & LOSERS: Marlowe up on report of potential division sale

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

ValiRx shares drop after cancer drug research dropped

(Alliance News) - ValiRx PLC shares fell on Friday, after it ended its evaluation agreement with Hokkaido University to research a potential drug.

LONDON MARKET OPEN: Stocks head higher as pound tops USD1.28 again

(Alliance News) - Stock prices in London opened higher on Friday, taking their cue from Asian and US equities, while investors weighed recent interest rate decisions.

ValiRx acquires assets of in-liquidation Imagen Therapeutics

(Sharecast News) - Life science company ValiRx has successfully completed the acquisition of the scientific assets of Imagen Therapeutics, it announced on Wednesday.

ValiRx buys Imagen's scientific assets for cancer screening services

(Alliance News) - ValiRx PLC on Wednesday said it acquired the scientific assets of Imagen Therapeutics Ltd from its appointed liquidators for GBP170,000.

ValiRx expands cancer research agreement with University of Barcelona

(Alliance News) - ValiRx PLC on Wednesday said it has expanded a pre-existing agreement with the University of Barcelona to test additional molecules as possible drugs for cancer.